About TransQST

One of the main focuses of TransQST are “off-target reactions” which cannot be predicted from the known pharmacological properties of the drug. The main organs of concern for such reactions are the liver, the kidney and the cardiovascular and gastrointestinal systems.

Professor Kevin Park, co-ordinator, said: “The fear of ADRs is a major impediment to the development of new, safe and effective therapies.

“This project will enable us to leverage the best available data and expertise from both public and private domains to generate and validate novel computational models that will help to address the problems of safe drug development.

“Our ultimate aim is to maximise the benefits of medicines and minimise the harm.”

The focus of the TransQST project will be to provide innovative methodologies and software tools for systems toxicology modelling. 

The TransQST project will:

  • Provide fit-for-purpose QST models addressing key toxicity outcomes for liver, kidney, heart and GI-tract.
  • Provide quantitative risk assessment for off-target toxicities in man based on in vitro and in vivo models.
  • Provide a quantitative mechanistic read-across from species (in vitro and in vivo) currently used for the toxicological evaluation of a new drug.
  • Provide definition and applicability of the human physiological and pharmacological relevance of preclinical test systems.
  • Provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man, and which relate to intracellular pathways (and systems) relevant to drug toxicity.